Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe

American Journal of Respiratory and Critical Care Medicine

Volumn 194, Issue 8, 2016, Pages 1029-1031

  Lange, Christoph ^a,b,c,d,e   Duarte, Raquel ^f   Fréchet Jachym, Mathilde ^g   Guenther, Gunar ^a,b,c,e   Guglielmetti, Lorenzo ^g,h   Olaru, Ioana D ^a,b,c   Oliveira, Olena ^f   Rumetshofer, Rudolf ⁱ   Veziris, Nicolas ^h,j   Van Leth, Frank ^k,l  

^a RESEARCH CENTER BORSTEL   (Germany)

^b German Center for Infection Research   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF NAMIBIA   (Namibia)

^f UNIVERSITY OF PORTO   (Portugal)

^g Bligny ICU   (France)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ OTTO WAGNER HOSPITAL   (Austria)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k UNIVERSITY OF AMSTERDAM   (Netherlands)

^l AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BIOLOGICAL MARKER; CAPREOMYCIN; CLOFAZIMINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADVERSE DRUG REACTION; CLINICAL EFFECTIVENESS; DRUG COST; EUROPE; HUMAN; LETTER; MEDICATION COMPLIANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT FAILURE; CLINICAL PROTOCOL; DRUG ADMINISTRATION; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; STANDARDS; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; ELIGIBILITY DETERMINATION; EUROPE; HUMANS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 84992323965     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201606-1097LE     Document Type: Letter

References (11)

1. World Health Organization. Global tuberculosis report 2015. Geneva, Switzerland: World Health Organization; 2015.
2. Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho ACC, Chang KC, Codecasa L, Correia A, Crudu V, et al.; TBNET. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014;44:23-63.
3. Heyckendorf J, Olaru ID, Ruhwald M, Lange C. Getting personal perspectives on individualized treatment duration in multidrugresistant and extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2014;190:374-383.
4. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, Switzerland: World Health Organization 2014.
5. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182: 684-692.
6. Kuaban C, Noeske J, Rieder HL, Ait-Khaled N, Abena Foe JL, Tré bucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015;19:517-524.
7. Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, Hanki Y, Van Deun A. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014;18:1188-1194.
8. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva, Switzerland: World Health Organization; 2016.
9. World Health Organization. The shorter MDR-TB regimen. 2016 [accessed 2016 Sept 14]. Available from: http://www.who.int/tb/Short-MDR-regimen-factsheet.pdf
10. Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Zumla A, Migliori GB. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet 2016;387:2486-2487.
11. Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, et al.; TBNET. Multidrug-resistant tuberculosis in Europe, 2010-2011. Emerg Infect Dis 2015;21:409-416.